Optimal antiplatelet therapy after revascularization of left subclavian artery during TEVAR.
Humans
Male
Female
Retrospective Studies
Platelet Aggregation Inhibitors
/ therapeutic use
Subclavian Artery
/ surgery
Middle Aged
Aortic Dissection
/ surgery
Endovascular Procedures
/ methods
Aortic Aneurysm, Thoracic
/ surgery
Aged
Clopidogrel
/ therapeutic use
Aspirin
/ therapeutic use
Aorta, Thoracic
/ surgery
Treatment Outcome
Blood Vessel Prosthesis Implantation
/ methods
Postoperative Complications
Endovascular Aneurysm Repair
Antiplatelet
Aortic dissection
Aspirin
Clopidogrel
Left subclavian artery revascularization
TEVAR
Journal
Journal of cardiothoracic surgery
ISSN: 1749-8090
Titre abrégé: J Cardiothorac Surg
Pays: England
ID NLM: 101265113
Informations de publication
Date de publication:
28 Jun 2024
28 Jun 2024
Historique:
received:
26
04
2024
accepted:
15
06
2024
medline:
28
6
2024
pubmed:
28
6
2024
entrez:
27
6
2024
Statut:
epublish
Résumé
Thoracic endovascular aortic repair (TEVAR) is a minimally invasive technique used to treat type B aortic dissections. Left subclavian artery (LSA) reconstruction is required when treating patients with involvement of LSA. The best antiplatelet therapy after LSA reconstruction is presently uncertain. This study retrospectively analyzed 245 type B aortic dissection patients who underwent left subclavian artery revascularization during TEVAR. Out of 245 patients, 159 (64.9%) were in the single antiplatelet therapy (SAPT) group, receiving only aspirin, and 86 (35.1%) were in the dual antiplatelet therapy (DAPT) group, receiving aspirin combined with clopidogrel. During the 6-month follow-up, primary endpoints included hemorrhagic events (general bleeding and hemorrhagic strokes), while secondary endpoints comprised ischemic events (left upper limb ischemia, ischemic stroke, and thrombotic events), as well as death and leakage events. Both univariate and multivariate Cox regression analyses were performed on hemorrhagic and ischemic events, with the Kaplan-Meier method used to generate the survival curve. During the six-month follow-up, the incidence of hemorrhagic events in the DAPT group was higher (8.2% vs. 30.2%, P < 0.001). No significant differences were observed in ischemic events, death, or leakage events among the different antiplatelet treatment schemes. Multivariate Cox regression analysis showed that DAPT (HR: 2.22, 95% CI: 1.07-4.60, P = 0.032) and previous chronic conditions (HR:3.88, 95% CI: 1.24-12.14, P = 0.020) significantly affected the occurrence of hemorrhagic events. Chronic conditions in this study encompassed depression, vitiligo, and cholecystolithiasis. Carotid subclavian bypass (CSB) group (HR:0.29, 95% CI: 0.12-0.68, P = 0.004) and single-branched stent graft (SBSG) group (HR:0.26, 95% CI: 0.13-0.50, P < 0.001) had a lower rate of ischemic events than fenestration TEVAR (F-TEVAR). Survival analysis over 6 months revealed a lower risk of bleeding associated with SAPT during hemorrhagic events (P = 0.043). In type B aortic dissection patients undergoing LSA blood flow reconstruction after synchronous TEVAR, the bleeding risk significantly decreases with the SAPT regimen, and there is no apparent ischemic compensation within 6 months. Patients with previous chronic conditions have a higher risk of bleeding. The CSB group and SBSG group have less ischemic risk compared to F-TEVAR group.
Sections du résumé
BACKGROUND
BACKGROUND
Thoracic endovascular aortic repair (TEVAR) is a minimally invasive technique used to treat type B aortic dissections. Left subclavian artery (LSA) reconstruction is required when treating patients with involvement of LSA. The best antiplatelet therapy after LSA reconstruction is presently uncertain.
METHODS
METHODS
This study retrospectively analyzed 245 type B aortic dissection patients who underwent left subclavian artery revascularization during TEVAR. Out of 245 patients, 159 (64.9%) were in the single antiplatelet therapy (SAPT) group, receiving only aspirin, and 86 (35.1%) were in the dual antiplatelet therapy (DAPT) group, receiving aspirin combined with clopidogrel. During the 6-month follow-up, primary endpoints included hemorrhagic events (general bleeding and hemorrhagic strokes), while secondary endpoints comprised ischemic events (left upper limb ischemia, ischemic stroke, and thrombotic events), as well as death and leakage events. Both univariate and multivariate Cox regression analyses were performed on hemorrhagic and ischemic events, with the Kaplan-Meier method used to generate the survival curve.
RESULTS
RESULTS
During the six-month follow-up, the incidence of hemorrhagic events in the DAPT group was higher (8.2% vs. 30.2%, P < 0.001). No significant differences were observed in ischemic events, death, or leakage events among the different antiplatelet treatment schemes. Multivariate Cox regression analysis showed that DAPT (HR: 2.22, 95% CI: 1.07-4.60, P = 0.032) and previous chronic conditions (HR:3.88, 95% CI: 1.24-12.14, P = 0.020) significantly affected the occurrence of hemorrhagic events. Chronic conditions in this study encompassed depression, vitiligo, and cholecystolithiasis. Carotid subclavian bypass (CSB) group (HR:0.29, 95% CI: 0.12-0.68, P = 0.004) and single-branched stent graft (SBSG) group (HR:0.26, 95% CI: 0.13-0.50, P < 0.001) had a lower rate of ischemic events than fenestration TEVAR (F-TEVAR). Survival analysis over 6 months revealed a lower risk of bleeding associated with SAPT during hemorrhagic events (P = 0.043).
CONCLUSIONS
CONCLUSIONS
In type B aortic dissection patients undergoing LSA blood flow reconstruction after synchronous TEVAR, the bleeding risk significantly decreases with the SAPT regimen, and there is no apparent ischemic compensation within 6 months. Patients with previous chronic conditions have a higher risk of bleeding. The CSB group and SBSG group have less ischemic risk compared to F-TEVAR group.
Identifiants
pubmed: 38937841
doi: 10.1186/s13019-024-02932-3
pii: 10.1186/s13019-024-02932-3
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Clopidogrel
A74586SNO7
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
402Subventions
Organisme : Jiangsu Provincial Health and Health Commission
ID : ZD2021023
Informations de copyright
© 2024. The Author(s).
Références
Volodos NL, Karpovich IP, Troyan VI, Kalashnikova Y, Shekhanin VE, Ternyuk NE, Neoneta AS, Ustinov NI, Yakovenko LF. Clinical experience of the use of self-fixing synthetic prostheses for remote endoprosthetics of the thoracic and the abdominal aorta and iliac arteries through the femoral artery and as intraoperative endoprosthesis for Aorta Reconstruction. Vasa Suppl. 1991;33:93–5.
pubmed: 1788781
Xie W, Xue Y, Li S, Jin M, Zhou Q, Wang D. Left subclavian artery revascularization in thoracic endovascular aortic repair: single Center’s clinical experiences from 171 patients. J Cardiothorac Surg. 2021;16(1):207. https://doi.org/10.1186/s13019-021-01593-w .
doi: 10.1186/s13019-021-01593-w
pubmed: 34330305
pmcid: 8325210
Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DJ, A Report of the American College of Cardiology Foundation/American Heart Association Task Force On Practice Guidelines, American Association for Thoracic Surgery. 2010 Accf/Aha/Aats/Acr/Asa/Sca/Scai/Sir/Sts/Svm Guidelines for the Diagnosis and Management of Patients with Thoracic Aortic Disease., American College of Radiology,American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons,and Society for Vascular Medicine. J AM Coll Cardiol. 2010; 55(14):e27-e129. https://doi.org/10.1016/j.jacc.2010.02.015 .
Riambau V, Bockler D, Brunkwall J, Cao P, Chiesa R, Coppi G, et al. editors. ‘s Choice - Management of Descending Thoracic Aorta Diseases: Clinical Practice Guidelines of the European Society for Vascular Surgery (Esvs). Eur J Vasc Endovasc. 2017; 53(1):4–52. https://doi.org/10.1016/j.ejvs.2016.06.005 .
Upchurch GJ, Escobar GA, Azizzadeh A, Beck AW, Conrad MF, Matsumura JS, et al. Society for vascular surgery clinical practice guidelines of thoracic endovascular aortic repair for descending thoracic aortic aneurysms. J Vasc Surg. 2021;73(1S):S55–83. https://doi.org/10.1016/j.jvs.2020.05.076 .
doi: 10.1016/j.jvs.2020.05.076
Luehr M, Etz CD, Berezowski M, Nozdrzykowski M, Jerkku T, Peterss S, et al. Outcomes after thoracic endovascular aortic repair with overstenting of the left subclavian artery. Ann Thorac Surg. 2019;107(5):1372–9. https://doi.org/10.1016/j.athoracsur.2018.10.051 .
doi: 10.1016/j.athoracsur.2018.10.051
pubmed: 30508536
Matsumura JS, Lee WA, Mitchell RS, Farber MA, Murad MH, Lumsden AB, Greenberg RK, Safi HJ, Fairman RM. The Society for vascular surgery practice guidelines: management of the left subclavian artery with thoracic endovascular aortic repair. J Vasc Surg. 2009;50(5):1155–8. https://doi.org/10.1016/j.jvs.2009.08.090 .
doi: 10.1016/j.jvs.2009.08.090
pubmed: 19878791
van der Vliet JA, Palamba HW, Scharn DM, van Roye SF, Buskens FG. Arterial Reconstruction for Subclavian Obstructive Disease: a comparison of extrathoracic procedures. Eur J Vasc Endovasc. 1995;9(4):454–8. https://doi.org/10.1016/s1078-5884(05)80015-2 .
doi: 10.1016/s1078-5884(05)80015-2
Canaud L, Morishita K, Gandet T, Sfeir J, Bommart S, Alric P, Mandelli M. Homemade Fenestrated stent-graft for thoracic endovascular aortic repair of Zone 2 aortic lesions. J Thorac Cardiov Sur. 2018;155(2):488–93. https://doi.org/10.1016/j.jtcvs.2017.07.045 .
doi: 10.1016/j.jtcvs.2017.07.045
Jing Z, Lu Q, Feng J, Zhou J, Feng R, Zhao Z, et al. Endovascular repair of aortic dissection involving the left subclavian artery by Castor Stent Graft: a Multicentre prospective trial. Eur J Vasc Endovasc. 2020;60(6):854–61. https://doi.org/10.1016/j.ejvs.2020.08.022 .
doi: 10.1016/j.ejvs.2020.08.022
Boakye E, Uddin S, Obisesan OH, Osei AD, Dzaye O, Sharma G, McEvoy JW, Blumenthal R, Blaha MJ. Aspirin for Cardiovascular Disease Prevention among adults in the United States: Trends, Prevalence, and participant characteristics Associated with Use. Am J Prev Cardiol. 2021;8:100256. https://doi.org/10.1016/j.ajpc.2021.100256 .
doi: 10.1016/j.ajpc.2021.100256
pubmed: 34632437
pmcid: 8488247
Rhee TG, Kumar M, Ross JS, Coll PP. Age-related trajectories of Cardiovascular Risk and Use of Aspirin and Statin among U.S. adults aged 50 or older, 2011–2018. J Am Geriatr Soc. 2021;69(5):1272–82. https://doi.org/10.1111/jgs.17038 .
doi: 10.1111/jgs.17038
pubmed: 33598936
pmcid: 9869399
Zheng SL, Roddick AJ. Association of Aspirin Use for Primary Prevention with Cardiovascular events and bleeding events: a systematic review and Meta-analysis. JAMA-J Am Med Assoc. 2019;321(3):277–87. https://doi.org/10.1001/jama.2018.20578 .
doi: 10.1001/jama.2018.20578
Calderone D, Greco A, Ingala S, Agnello F, Franchina G, Scalia L, Buccheri S, Capodanno D. Efficacy and safety of aspirin for Primary Cardiovascular Risk Prevention in younger and older age: an updated systematic review and Meta-analysis of 173,810 subjects from 21 Randomized studies. Thromb Haemostasis. 2022;122(3):445–55. https://doi.org/10.1055/a-1667-7427 .
doi: 10.1055/a-1667-7427
Pan Y, Elm JJ, Li H, Easton JD, Wang Y, Farrant M, et al. Outcomes Associated with Clopidogrel-Aspirin Use in Minor Stroke or transient ischemic attack: a pooled analysis of Clopidogrel in High-Risk patients with Acute Non-disabling cerebrovascular events (chance) and platelet-oriented inhibition in New Tia and minor ischemic stroke (point) trials. JAMA Neurol. 2019;76(12):1466–73. https://doi.org/10.1001/jamaneurol.2019.2531 .
doi: 10.1001/jamaneurol.2019.2531
pubmed: 31424481
pmcid: 6704730
Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk Tia. New Engl J Med. 2018;379(3):215–25. https://doi.org/10.1056/NEJMoa1800410 .
doi: 10.1056/NEJMoa1800410
pubmed: 29766750
He RX, Zhang L, Zhou TN, Yuan WJ, Liu YJ, Fu WX, Jing QM, Liu HW, Wang XZ. Safety and Necessity of Antiplatelet Therapy on patients underwent endovascular aortic repair with both Stanford Type B aortic dissection and Coronary Heart Disease. Chin Med J-Peking. 2017;130(19):2321–5. https://doi.org/10.4103/0366-6999.215330 .
doi: 10.4103/0366-6999.215330
Hansson EC, Geirsson A, Hjortdal V, Mennander A, Olsson C, Gunn J, et al. Preoperative dual antiplatelet therapy increases bleeding and transfusions but not mortality in Acute Aortic dissection type a repair. Eur J Cardio-Thorac. 2019;56(1):182–8. https://doi.org/10.1093/ejcts/ezy469 .
doi: 10.1093/ejcts/ezy469
Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for Cardiovascular clinical trials: a Consensus Report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736–47. https://doi.org/10.1161/CIRCULATIONAHA.110.009449 .
doi: 10.1161/CIRCULATIONAHA.110.009449
pubmed: 21670242
Huang Q, Chen XM, Yang H, Lin QN, Qin X. Effect of left subclavian artery revascularisation in thoracic endovascular aortic repair: a systematic review and Meta-analysis. Eur J Vasc Endovasc. 2018;56(5):644–51. https://doi.org/10.1016/j.ejvs.2018.07.018 .
doi: 10.1016/j.ejvs.2018.07.018
Bradshaw RJ, Ahanchi SS, Powell O, Larion S, Brandt C, Soult MC, Panneton JM. Left subclavian artery revascularization in Zone 2 thoracic endovascular aortic repair is Associated with Lower Stroke Risk Across All Aortic diseases. J Vasc Surg. 2017;65(5):1270–9. https://doi.org/10.1016/j.jvs.2016.10.111 .
doi: 10.1016/j.jvs.2016.10.111
pubmed: 28216353
Zamor KC, Eskandari MK, Rodriguez HE, Ho KJ, Morasch MD, Hoel AW. Outcomes of thoracic endovascular aortic repair and subclavian revascularization techniques. J Am Coll Surg. 2015;221(1):93–100. https://doi.org/10.1016/j.jamcollsurg.2015.02.028 .
doi: 10.1016/j.jamcollsurg.2015.02.028
pubmed: 25872688
pmcid: 4478203
Wu X, Li Y, Zhao Y, Zhu Y, Wang S, Ma Q, et al. Efficacy of left subclavian artery revascularization strategies during thoracic endovascular aortic repair in patients with type B dissection: a single-center experience of 105 patients. Front Cardiovasc Med. 2023;10:1084851. https://doi.org/10.3389/fcvm.2023.1084851 .
doi: 10.3389/fcvm.2023.1084851
pubmed: 37077745
pmcid: 10106686
Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ. Acc/Aha Versus Esc Guidelines On Dual Antiplatelet Therapy: Jacc Guideline Comparison. J Am Coll Cardiol. 2018; 72(23 Pt A):2915–31. https://doi.org/10.1016/j.jacc.2018.09.057 .
von Allmen RS, Gahl B, Powell JT, editors. ‘s Choice - Incidence of Stroke Following Thoracic Endovascular Aortic Repair for Descending Aortic Aneurysm: A Systematic Review of the Literature with Meta-Analysis. Eur J Vasc Endovasc. 2017; 53(2):176–84. https://doi.org/10.1016/j.ejvs.2016.10.025 .
Capranzano P, Moliterno D, Capodanno D. Aspirin-free antiplatelet strategies after percutaneous coronary interventions. Eur Heart J. 2024;45(8):572–85. https://doi.org/10.1093/eurheartj/ehad876 .
doi: 10.1093/eurheartj/ehad876
pubmed: 38240716
Beiswenger AC, Jo A, Harth K, Kumins NH, Shishehbor MH, Kashyap VS. A systematic review of the efficacy of aspirin Monotherapy Versus Other Antiplatelet Therapy regimens in Peripheral arterial disease. J Vasc Surg. 2018;67(6):1922–32. https://doi.org/10.1016/j.jvs.2018.02.047 .
doi: 10.1016/j.jvs.2018.02.047
pubmed: 29801560
Yang S, Kang J, Park KW, Hur SH, Lee NH, Hwang D, et al. Comparison of Antiplatelet monotherapies after percutaneous coronary intervention according to clinical, ischemic, and bleeding risks. J Am Coll Cardiol. 2023;82(16):1565–78. https://doi.org/10.1016/j.jacc.2023.07.031 .
doi: 10.1016/j.jacc.2023.07.031
pubmed: 37821166